Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents
AbstractAimsThe demonstration that endothelin production is upregulated in pulmonary artery hyperten...
First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of actions t...
Endothelin 1 (ET-1) is a potent pulmonary vasoconstrictor and me-diator of lung diseases. Antagonism...
The endothelin system, and in particular endothelin receptors, are targets for therapeutic intervent...
acid peptide and currently the most potent vasoconstrictor and pressor substance known. Generated by...
Clinical trials have established bosentan, an orally active non-selective endothelin (ET) receptor a...
Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent ye...
International audiencePulmonary arterial hypertension (PAH) is a devastating life-threatening disord...
© 2013 Richard James Alexander HughesEndothelin-1 is a potent vasoactive peptide and has been sugges...
AbstractEndothelin receptor antagonism has emerged as an important therapeutic strategy in pulmonary...
Endothelin, a 21-amino-acid peptide, binds to a specific receptor on vascular smooth muscle cells, t...
Our understanding of the role of the endothelin system in human cardiovascular physiology and pathop...
Endothelin, a 21-amino-acid peptide, binds to a specific receptor on vascular smooth muscle cells, t...
Endothelins (ET) are a group of endogenous peptides, which have a strong and long-lasting vasocon-st...
International audienceEndothelin: From discovery to pharmacotherapeutic innovations Objectives > End...
AbstractAimsThe demonstration that endothelin production is upregulated in pulmonary artery hyperten...
First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of actions t...
Endothelin 1 (ET-1) is a potent pulmonary vasoconstrictor and me-diator of lung diseases. Antagonism...
The endothelin system, and in particular endothelin receptors, are targets for therapeutic intervent...
acid peptide and currently the most potent vasoconstrictor and pressor substance known. Generated by...
Clinical trials have established bosentan, an orally active non-selective endothelin (ET) receptor a...
Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent ye...
International audiencePulmonary arterial hypertension (PAH) is a devastating life-threatening disord...
© 2013 Richard James Alexander HughesEndothelin-1 is a potent vasoactive peptide and has been sugges...
AbstractEndothelin receptor antagonism has emerged as an important therapeutic strategy in pulmonary...
Endothelin, a 21-amino-acid peptide, binds to a specific receptor on vascular smooth muscle cells, t...
Our understanding of the role of the endothelin system in human cardiovascular physiology and pathop...
Endothelin, a 21-amino-acid peptide, binds to a specific receptor on vascular smooth muscle cells, t...
Endothelins (ET) are a group of endogenous peptides, which have a strong and long-lasting vasocon-st...
International audienceEndothelin: From discovery to pharmacotherapeutic innovations Objectives > End...
AbstractAimsThe demonstration that endothelin production is upregulated in pulmonary artery hyperten...
First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of actions t...
Endothelin 1 (ET-1) is a potent pulmonary vasoconstrictor and me-diator of lung diseases. Antagonism...